Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qishen'gubiao Granule in asymptomatic Omicron-infected patients
ChiCTR2200060016Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of Qishen'gubiao Granule in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Average time to nucleic acid negativity. Planned start May 2022; status: not yet recruiting.
02
Drugs
Qishen'gubiao Granule
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200060016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060016.